Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

First human dMAb study will target Zika infection
May 2019
SHARING OPTIONS:

PLYMOUTH MEETING, Pa.—Inovio Pharmaceuticals Inc., in collaboration with The Wistar Institute and the University of Pennsylvania, announced in late March the initiation of the first human study of its DNA-encoded monoclonal antibody (dMAb) technology to prevent Zika virus infection, examining the candidate INO-A002. When delivered directly into the body, the genetic instructions provided by the designed synthetic dMAbs reportedly instruct the body’s cells to become the factory which manufactures the therapeutic antibody products, enabling what Inovio called “a major leap in antibody technology.” This open-label trial is a single-center, dose-escalation trial that will enroll up to 24 healthy volunteers who will receive up to four doses of INO-A002.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.